We are monitoring the impact of COVID-19 on Europe Biomarkers Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 166
Share on
Share on

Europe Biomarkers Market Research Report – segmented By Product, Type, Disease Indications & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 166
Pages: 145

Europe Biomarkers Market Size (2021 to 2026)

The European biomarkers market's size is expected to be worth USD 21.52 billion by 2026 from USD 11.73 billion in 2021, growing at a CAGR of 12.90% during the forecast period.

Increased diagnostic uses of biomarkers, increased funding for pharma and biotech businesses, a rapidly growing number of contract research organizations, low cost of clinical trials in developing countries, high cancer prevalence, and new research efforts are all driving growth in the European biomarkers market. The research also includes discovering biomarkers based on genetic data in the context of resistance, which might help predict radiation therapy responses and prognoses. As a result, the high prevalence of cancer and increased R&D efforts are projected to improve the market's overall growth. As the need for cost-effective and efficient treatment doses grows, biomarkers enable pharmaceutical companies to evaluate and develop novel medicines. To simplify the discovery and development of new medicines, biomarkers are utilized in drug validation and testing, sample preparation, and assay development. The biomarkers market is also gaining traction due to several factors, including an increase in diagnosis applications for companion diagnostics and personalized medicine, a fall in the cost of clinical trials in various emerging economies, and an increase in biotechnology and pharmaceutical company's investment in research and development.

Due to the rising prevalence of cancer, the use of cancer biomarkers has risen dramatically in recent years, giving opportunities to improve cancer patient care by boosting diagnosis and treatment efficacy. Personalized medications, companion diagnostics, disease risk assessment all use biomarkers extensively. Biomarkers' growing diagnostic applications are likely to fuel market expansion in the coming years. The rising disease burden and the bigger population in this region are key factors in higher growth prospects for these areas. In addition, the increasing number of hospitals in these areas presents significant opportunities for biomarker producers. With the advancement of technology in clinical laboratory testing, imaging exams, and biomarker tests, the market for diagnostic biomarkers is increasing. In recent years, biomarker tests have influenced patient clinical care. Biomarkers are usually identified by examining pathophysiology and epidemiology, both of which provide insensitive and nonspecific indicators. The rising frequency of chronic heart illnesses, particularly heart attacks, in Europe offers attractive prospects in the biomarkers industry.

The major factors limiting the growth of the European biomarkers market are high capital investments and low cost-benefit ratios, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage. The high costs of biomarker validation are a big challenge for businesses, particularly firms. In addition, intrinsic fluctuation in biomarker levels and molecular heterogeneity add to the difficulties in the biomarker validation process.

This research report on the European Biomarkers Market has been segmented and sub-segmented into the following categories:

By Product: 

  • Consumables
  • Software
  • Services

By Type: 

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Validation Biomarkers

By Application: 

  • Diagnostics Developments
  • Drug Discovery & Developments
  • Personalized Medicine
  • Disease Risk Assessment

By Disease Indications: 

  • Cancer
  • Cardiovascular
  • Neurological
  • Immunological Disorders

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the biomarkers market in Europe is expected to develop rapidly over the forecast period, owing to increased drug discovery activities. The rising incidence of cancer and the increased focus on new medication development are two reasons propelling the industry forward. Early detection based on biomarkers allows for sensitive and cost-effective testing, which is predicted to lower cancer mortality. In addition, the biomarker's ability to properly measure risk has aided in increasing technology acceptance, which has resulted in market expansion.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the European biomarkers market profiled in this report are Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Enzo Biochem (U.S.), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), EKF Diagnostics Holdings plc. (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).

  1. Introduction

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

  1. Research Methodology

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

  1. Overview

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

  1. Market Segmentation

                5.1          Product                                               

                                5.1.1 Introduction                                           

                                5.1.2 Consumables                                         

                                5.1.3 Software                                  

                                5.1.4 Services     Growth Hormone Therapy                         

                5.2          Type                                     

                                5.2.1 Introduction                                           

                                5.2.2 Safety Biomarkers                                               

                                5.2.3 Efficacy Biomarkers                                             

                                5.2.4 Validation Biomarkers                                        

                5.3          Application                                        

                                5.3.1 Introduction                                           

                                5.3.2 Diagnostics Development                                 

                                5.3.3 Drug Discovery and Development                                

                                5.3.4 Personalised Medicine                                      

                                5.3.5 Disease Risk Assessment                                  

                                5.3.6 Other Applications                                               

                5.4          Disease Indications                                        

                                5.4.1 Introduction                                           

                                5.4.2 Cancer                                      

                                5.4.3 CardiovascularDisorders                                    

                                5.4.4 Neurological Disorders                                       

                                5.4.5 Immunological Disorders                                  

                                5.4.6 Other Diseases                                      

  1. Geographical Analysis

                                6.1 Introduction                                               

                                6.2 U.K                                 

                                6.3 Spain                                             

                                6.4 Germany                                     

                                6.5 Italy                                               

                                6.6 France                                          

  1. Strategic Analysis

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

  1. Market Leaders' Analysis

                8.1 Bio-Rad Laboratories (U.S.)                                 

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                             

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Qiagen N.V. (Netherlands)                                  

                8.3 Enzo Biochem (U.S.)                                               

                8.4 PerkinElmer, Inc. (U.S.)                                         

                8.5 Merck & Co, Inc. (U.S.)                                          

                8.6 EKF Diagnostics Holdings plc. (U.S.)                                  

                8.7 Meso Scale Diagnostics, LLC (U.S.)                                    

                8.8 Singulex, Inc. (U.S.)                                 

                8.9 BioSims Technologies (France)                                           

                8.10 Cisbio Bioassays (France)                                   

                8.11 Signosis, Inc. (U.S.)                                               

  1. Competitive Landscape

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

     Appendix                                                                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Biomarkers Market, By Region, From 2021 to 2026 (USD Million)
  2. Europe Biomarkers Market, By Product, From 2021 to 2026 (USD Million)
  3. Europe Consumables Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Software Market, By Region, From 2021 to 2026 (USD Million)
  5. Europe Services Market, By Region, From 2021 to 2026 (USD Million)
  6. Europe Biomarkers Market, By Type, From 2021 to 2026 (USD Million)
  7. Europe Safety Biomarkers Market, By Region, From 2021 to 2026 (USD Million)
  8. Europe Efficacy Biomarkers Market, By Region, From 2021 to 2026 (USD Million)
  9. Europe Validation Biomarkers Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe Biomarkers Market, By Application, From 2021 to 2026 (USD Million)
  11. Europe Diagnostics Development Market, By Region, From 2021 to 2026 (USD Million)
  12. Europe Drug Discovery and Development Market, By Region, From 2021 to 2026 (USD Million)
  13. Europe Personalised Medicine Market, By Region, From 2021 to 2026 (USD Million)
  14. Europe Disease Risk Assessment Market, By Region, From 2021 to 2026 (USD Million)
  15. Europe Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  16. Europe Biomarkers Market, By Disease Indications, From 2021 to 2026 (USD Million)
  17. Europe Cancer Market, By Region, From 2021 to 2026 (USD Million)
  18. Europe Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Million)
  19. Europe Neurological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  20. Europe Immunological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  21. Europe Other Diseases Market, By Region, From 2021 to 2026 (USD Million)
  22. U.K. Biomarkers Market, By Product, From 2021 to 2026 (USD Million)
  23. U.K. Biomarkers Market, By Type, From 2021 to 2026 (USD Million)
  24. U.K. Biomarkers Market, By Application, From 2021 to 2026 (USD Million)
  25. U.K. Biomarkers Market, By Disease Indications, From 2021 to 2026 (USD Million)
  26. Germany Biomarkers Market, By Product, From 2021 to 2026 (USD Million)
  27. Germany Biomarkers Market, By Type, From 2021 to 2026 (USD Million)
  28. Germany Biomarkers Market, By Application, From 2021 to 2026 (USD Million)
  29. Germany Biomarkers Market, By Disease Indications, From 2021 to 2026 (USD Million)
  30. France Biomarkers Market, By Product, From 2021 to 2026 (USD Million)
  31. France Biomarkers Market, By Type, From 2021 to 2026 (USD Million)
  32. France Biomarkers Market, By Application, From 2021 to 2026 (USD Million)
  33. France Biomarkers Market, By Disease Indications, From 2021 to 2026 (USD Million)
  34. Italy Biomarkers Market, By Product, From 2021 to 2026 (USD Million)
  35. Italy Biomarkers Market, By Type, From 2021 to 2026 (USD Million)
  36. Italy Biomarkers Market, By Application, From 2021 to 2026 (USD Million)
  37. Italy Biomarkers Market, By Disease Indications, From 2021 to 2026 (USD Million)
  38. Spain Biomarkers Market, By Product, From 2021 to 2026 (USD Million)
  39. Spain Biomarkers Market, By Type, From 2021 to 2026 (USD Million)
  40. Spain Biomarkers Market, By Application, From 2021 to 2026 (USD Million)
  41. Spain Biomarkers Market, By Disease Indications, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample